SCYNEXIS (SCYX) to Release Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect SCYNEXIS to post earnings of $0.1267 per share and revenue of $8.10 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 7:00 AM ET.

SCYNEXIS (NASDAQ:SCYX) last released its earnings results on Wednesday, March 4th. The company reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.04). SCYNEXIS had a negative return on equity of 25.52% and a negative net margin of 41.79%.The firm had revenue of $17.20 million for the quarter, compared to analyst estimates of $8.10 million.

SCYNEXIS Price Performance

SCYX stock opened at $0.79 on Tuesday. The stock has a market capitalization of $35.27 million, a price-to-earnings ratio of -4.65 and a beta of 1.32. The company has a 50-day moving average of $0.80 and a two-hundred day moving average of $0.75. SCYNEXIS has a 52-week low of $0.57 and a 52-week high of $1.31.

Analysts Set New Price Targets

SCYX has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of SCYNEXIS in a research report on Monday, December 29th. reaffirmed a “buy” rating on shares of SCYNEXIS in a report on Monday, March 9th. Finally, Wall Street Zen raised SCYNEXIS from a “hold” rating to a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $3.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SCYX. Jane Street Group LLC bought a new position in shares of SCYNEXIS during the 2nd quarter worth about $27,000. Bridgeway Capital Management LLC lifted its stake in shares of SCYNEXIS by 4.2% in the second quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock valued at $248,000 after buying an additional 14,689 shares during the period. Geode Capital Management LLC lifted its stake in shares of SCYNEXIS by 7.1% in the fourth quarter. Geode Capital Management LLC now owns 449,223 shares of the company’s stock valued at $284,000 after buying an additional 29,775 shares during the period. Goldman Sachs Group Inc. acquired a new stake in SCYNEXIS during the fourth quarter worth about $1,255,000. Finally, Vanguard Group Inc. grew its position in SCYNEXIS by 6.4% during the third quarter. Vanguard Group Inc. now owns 1,762,322 shares of the company’s stock worth $1,357,000 after buying an additional 105,600 shares in the last quarter. Institutional investors own 54.37% of the company’s stock.

SCYNEXIS Company Profile

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.